Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Precision BioSciences ( (DTIL) ).
On May 14, 2025, Precision BioSciences announced the acceleration of its PBGENE-DMD program, a first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD), highlighting preclinical evidence at the ASGCT Annual Meeting. The program aims to address the significant unmet need for DMD treatments by restoring the body’s production of functional dystrophin protein, potentially offering a durable intervention for most patients. Precision plans to submit an IND and/or CTA in 2025, with clinical data expected in 2026, while pausing development of PBGENE-3243 to focus on advancing PBGENE-DMD and PBGENE-HBV through Phase 1 clinical results.
The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.
Spark’s Take on DTIL Stock
According to Spark, TipRanks’ AI Analyst, DTIL is a Neutral.
Precision BioSciences shows strong revenue growth and low debt levels, contributing to a stable financial position. However, profitability and cash flow challenges weigh on its financial performance. The technical analysis suggests potential short-term upward momentum, but the stock remains below its 200-day moving average, indicating caution for long-term trends. The valuation is attractive with a low P/E ratio, suggesting the stock might be undervalued. Overall, while there are promising indicators, significant focus on improving cash flow and profitability is needed for a more favorable outlook.
To see Spark’s full report on DTIL stock, click here.
More about Precision BioSciences
Precision BioSciences, Inc. is a clinical stage gene editing company that utilizes its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need. The company’s lead programs include PBGENE-HBV for chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy, focusing on areas with large patient populations lacking adequate treatments.
Average Trading Volume: 157,844
Technical Sentiment Signal: Sell
Current Market Cap: $55.07M
See more insights into DTIL stock on TipRanks’ Stock Analysis page.